MedTrace Logo

A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects

NCT05875259 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-09-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetic interaction and safety between BR1019-1 and BR1019-2 in healthy adult subjects.

Conditions

Interventions

DRUG

BR1019-1

Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.

DRUG

BR1019-2

Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.

DRUG

BR1019-1 + BR1019-2

Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-13
Primary Completion
2023-06-29
Completion
2023-06-29

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05875259 on ClinicalTrials.gov